Global Drug Discovery Outsourcing Market Report 2022: A $6.3 Billion Industry by 2030 with Small Molecules Dominating the Market in 2021

2022-06-28
PRNewswire
疫苗小分子药物合作
DUBLIN, June 28, 2022 /PRNewswire/ -- The "Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report by Drug Type (Small, Large Molecules), by Therapeutic Area (Respiratory System, Immunomodulation), by Workflow, and Segment Forecasts, 2022-2030" report has been added to
ResearchAndMarkets.com's offering.
The global drug discovery outsourcing market size is expected to reach USD 6.3 billion by 2030 at a CAGR of 7.4%
The COVID-19 pandemic has brought pharmaceutical companies in limelight. Drug discovery is a costly and lengthy process. This has urged pharmaceutical and biotech companies to opt for outsourcing their research activities to academic and private Contract Research Organizations (CROs).
Rising partnerships between public or private entities accelerate drug discovery processes, which, in turn, increase the global demand for outsourcing services for drug discovery.
This scenario is expected to sustain post the covid implications as well. A rise in cases of chronic diseases has urged companies to develop medicines that extend life expectancy. According to the United Nations, people aged 65 years between 2015 and 2020 are expected to live an additional 17 years.
Some of the key therapeutic areas where companies are actively involved in outsourcing include oncology, cardiovascular, and anti-infectives. In November 2020, AstraZeneca collaborated with 9 of the foremost oncology medical centers to expedite research in some of the hardest-to-treat cancers. The company will be funding clinical and non-clinical research proposals from members of this network.
The COVID-19 pandemic has demonstrated the value of drug discovery and development. People across the world are waiting for a vaccine while several companies are proactively involved in developing an effective vaccine to combat COVID-19.
Pfizer Inc. and BioNTech SE received first approval for the vaccine following a worldwide Phase 3 trial of a potential strain to combat the virus. As for clinical trials, many of them are halted, while some are functional by adopting remote monitoring technologies.
Thus, the pandemic has brought the pharmaceutical industry to center stage with drug discovery outsourcing becoming a key aspect to develop effective treatments against the virus. This is expected to boost the market revenue for the next 2 years i.e. a short-term boom, after which it shall regain its original growth curve.
Drug Discovery Outsourcing Market Report Highlights
In 2021, the lead identification & candidate optimization segment dominated the market. It is one of the most critical processes in drug discovery.
Oncology and anti-infective are projected to be among the fastest-growing segments during the forecast period.
Small molecules dominated the market in 2021. The segment is also projected to register a high CAGR during the forecast period. This, however, may change in the short term with higher emphasis on biologics.
Asia Pacific is projected to be the fastest-growing regional market during the forecast period.
The growth can be attributed to the government initiatives to forge alliances with U.S. pharmaceutical companies.
Key Topics Covered:
Chapter 1. Methodology and Scope
2.1. Market Outlook
2.2. Segment Outlook
Chapter 3. Drug Discovery Outsourcing Market Variables, Trends & Scope
3.1. Penetration & Growth Prospect Mapping
3.2. Industry Value Chain Analysis
3.2.1. Reimbursement framework
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.3.3. Industry challenges
3.4. Drug Discovery Outsourcing Market Analysis Tools
3.4.1. Industry Analysis-Porter's
3.4.2. PESTEL Analysis
3.4.3. Major Deals & Strategic Alliances Analysis
3.4.4. Market Entry Strategies
Chapter 4. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Definitions and Scope
4.3. Drug Discovery Outsourcing Market Share, 2021 & 2030
4.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
4.4.1. Target Identification & Screening
4.4.2. Target Validation & Functional Informatics
4.4.3. Lead Identification & Candidate Optimization
4.4.5. Other Associated Workflow
Chapter 5. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Definitions and Scope
5.3. Drug Discovery Outsourcing Market Share, 2021 & 2030
5.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
5.4.1. Respiratory System
5.4.2. Pain and Anesthesia
5.4.3. Oncology
5.4.4. Ophthalmology
5.4.5. Hematology
5.4.7. Endocrine
5.4.9. Immunomodulation
5.4.11. Central Nervous System
5.4.12. Dermatology
5.4.13. Genitourinary System
Chapter 6. Drug Discovery Outsourcing Market: Drug Type Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Definitions and Scope
6.3. Drug Discovery Outsourcing Market Share, 2021 & 2030
6.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
6.4.1. Small Molecules
6.4.2. Large Molecules (Biopharmaceuticals)
Chapter 7. Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2021 & 2030
7.3. Regional Market Share, 2020
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, by Key Market Participants
Laboratory Corporation of America Holdings
Ppd Inc
Qiagen
For more information about this report visit https://www.researchandmarkets.com/r/b693cc
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。